Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.50 |
| ▸ | AMD1 | P17707 | 2/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795966 | 1.00 | RXFP1 (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1795275 | 1.00 | RXFP1 (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1795964 | 1.00 | RXFP1 (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14429084 | 0.92 | TYMP (0.52) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24146635 | 0.89 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21377709 | 0.89 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2291014 | 0.89 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30546911 | 0.89 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25756772 | 0.89 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25756742 | 0.89 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1848718-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006084281-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20050124574-A1 | Purine derivatives | PFIZER INC. | 2005-06-09 | — | — | US | disclosed |
| US-6900309-B1 | Purine derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1185542-A2 | PURINE DERIVATIVES | Pfizer Limited (GB) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000077018-A2 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | RXFP1 3880/4885PI4KA 1455/4885PI4K2B 2027/4885 |
| US-20050124574-A1 | Purine derivatives | ADORA2A, ADORA3, ADORA1 | RXFP1 334/4885PI4KA 2517/4885PI4K2B 3186/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | RXFP1 3167/4885PI4KA 1991/4885PI4K2B 2891/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | RXFP1 3167/4885PI4KA 1991/4885PI4K2B 2891/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | RXFP1 3167/4885PI4KA 1991/4885PI4K2B 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.